This is a phase I, single-center, open-label, fixed-sequence clinical study. The primary
objective was to evaluate the effects of multiple administrations of rifampin or itraconazole
on the pharmacokinetic characteristics of a single administration of orelabrutinib tablets in
healthy Chinese subjects. The secondary objective was to evaluate the safety and tolerability
of rifampicin or itraconazole combined with orelabrutinib tablets in healthy Chinese
subjects.